Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Lin Y, et al. Among authors: hege k. Nat Med. 2023 Sep;29(9):2286-2294. doi: 10.1038/s41591-023-02496-0. Epub 2023 Aug 17. Nat Med. 2023. PMID: 37592106 Free PMC article. Clinical Trial.
Clinical characteristics, treatment, and outcomes of provoked acute cerebral sinovenous thrombosis in patients <21 years old: findings from the Kids-DOTT Multinational Trial.
Woods GM, Miller A, Mosha M, Male C, Verma A, Kucine N, Sabapathy C, Beg K, Ahuja S, Raybagkar D, Hege K, Lo C, Bhat R, Abshire T, Goldenberg NA. Woods GM, et al. Among authors: hege k. Res Pract Thromb Haemost. 2024 Oct 23;8(7):102605. doi: 10.1016/j.rpth.2024.102605. eCollection 2024 Oct. Res Pract Thromb Haemost. 2024. PMID: 39624586 Free PMC article.
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years.
Goldenberg NA, Schulman S, Kittelson JM, Abshire TC, Casella JF, Dale R, Halperin JL, Hanson J, Kessler CM, Manco-Johnson MJ, McDevitt L, Sidonio RF, Spyropoulos AC, Steg PG, Bonaca MP; Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) Trial Investigators and the Antithrombotic Trials Leadership and Steering (ATLAS) Group. Goldenberg NA, et al. J Thromb Haemost. 2024 Oct 24:S1538-7836(24)00631-7. doi: 10.1016/j.jtha.2024.09.038. Online ahead of print. J Thromb Haemost. 2024. PMID: 39461724
What is in a name: defining pediatric refractory ITP.
Nakano TA, Grimes AB, Klaassen RJ, Lambert MP, Neunert C, Rothman JA, Shimano KA, Amend C, Askew M, Badawy SM, Baker JM, Breakey V, Crary S, Davini M, Fritch Lilla S, Gilbert M, Hays T, Hege K, Hillier K, Jacobson-Kelly A, Kaicker S, Kim TO, Kochhar M, Leblanc T, Martinelli M, Nunez M, Remiker A, Schultz C, Sharma R, Grace RF. Nakano TA, et al. Among authors: hege k. Blood Adv. 2024 Oct 8;8(19):5112-5117. doi: 10.1182/bloodadvances.2024012707. Blood Adv. 2024. PMID: 39059013 Free PMC article.
Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium.
Abrams CM, Jaffray J, Stillings A, Branchford BR, Young G, Goldenberg NA, Abajas YL; CHAT Consortium Investigators; VTE Risk Factors and Thromboprophylaxis Working Group of the Pediatric and Neonatal Thrombosis and Hemostasis Subcommittee of the ISTH SSC; Fargo J, Crary S, Kumar R, Woods G, Narang S, Cooper J, Silvey M, Garland K, Mahajerin A, Luchtman-Jones L, Torres M, Wright J, Pahl K, Armstrong K, Braunreiter C, Bakeer N, Sochet A, Hogan M, Gupta S, Knoll C, Hege K, Schaefer B, Panigrahi A, Thornburg C, Shimano K, Ahuja S, Weyand A, Boucher A, Abajas Y, Subbaswamy A, Khan O, Druzgal C, Maida D, Wheeler A, Malec L, Branchford B, Kucine NE, Prozora S. Abrams CM, et al. Among authors: hege k. Res Pract Thromb Haemost. 2022 Dec 27;6(7):e12793. doi: 10.1002/rth2.12793. eCollection 2022 Oct. Res Pract Thromb Haemost. 2022. PMID: 38024326 Free PMC article.
Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
Shah N, Delforge M, San-Miguel J, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Miera M, Williams A, Murphy R, Devlen J, Hege K, Campbell TB, Munshi NC. Shah N, et al. Among authors: hege k. Leuk Res. 2022 Sep;120:106921. doi: 10.1016/j.leukres.2022.106921. Epub 2022 Jul 21. Leuk Res. 2022. PMID: 35930999 Free article.
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S, Haeske H, Hege K, Pourdehnad M, Kuruvilla J. Ribrag V, et al. Among authors: hege k. EJHaem. 2022 Jan 14;3(1):139-153. doi: 10.1002/jha2.375. eCollection 2022 Feb. EJHaem. 2022. PMID: 35846221 Free PMC article.
86 results